Stephan Schubert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephan Schubert has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
- Felix Berger
Department of Congenital Heart Disease—Pediatric Cardiology, Deutsches Herzzentrum der Charité, Augustenburger Platz 1, 13353 Berlin, Germany
6 shared publications - Karin Klingel
Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany
5 shared publications - Franziska Seidel
German Heart Center Berlin
4 shared publications - Peter Kramer
Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin Berlin Germany
4 shared publications - Bernd Opgen-Rhein
Department of Congenital Heart Disease—Pediatric Cardiology, Deutsches Herzzentrum der Charité, Charité—Universitätsmedizin Berlin, 13353 Berlin, Germany
3 shared publications - Hendrik Milting
Heart and Diabetescenter NRW, University Hospital of the Ruhr-University Bochum
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (6)
Age-associated clinical patterns in paediatric myocarditis: left ventricular function as the key early risk stratifier
Background and Aims: In myocarditis, early identification of high-risk patients is essential, but robust prognostic markers are lacking. We aimed to identify early clinical risk stratifiers at index hospitalization for major adverse cardiovascular events (MACE). Methods: We analysed 725 paediatric patients with possible/definite myocarditis enrolled in the prospective multicentre MYKKE registry (2013–24). Major adverse cardiovascular events included mechanical circulatory support (MCS), heart transplantation, or death during the initial admission. Model-based recursive partitioning and bootstrap-based logistic regression with multiple imputations were applied for risk stratifier selection out of 20 baseline variables. The model was externally validated in the Swedish SWEDCON cohort (n = 243). Discrimination was assessed by the area under the curve (AUC). Results: Among 725 patients [median age 14.3 years (IQR 4.0–16.4); 33% female], 88 (12.2%) experienced MACE (MCS 10.9%, transplantation 4.3%, death 2.2%). Model-based recursive partitioning identified left ventricular ejection fraction (LVEF) ≤39% as the only stable risk stratifier, delineating a ‘heart failure type’ in younger children (1.9 years; LVEF 24%), and a ‘chest pain type’ in adolescents with preserved LVEF (15.6 years; LVEF 59%). Left ventricular ejection fraction was confirmed as the sole robust risk stratifier (OR per 1% increase: .90; 95% CI .881–.917; P < .01; AUC .90, 95% CI .896–.903). In SWEDCON (7.4% MACE), discrimination was maintained (AUC .894, 95% CI .80–.991). Conclusion: Reduced LVEF at presentation was the only reproducible and externally validated risk stratifier of MACE during index hospitalization. Two age-associated clinical patterns were observed: a high-risk ‘heart failure type’ in younger children and low-risk ‘chest pain type’ in adolescents.
- 15 October 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (6)
Open AccessAge-associated clinical patterns in paediatric myocarditis: left ventricular function as the key early risk stratifier
Background and Aims: In myocarditis, early identification of high-risk patients is essential, but robust prognostic markers are lacking. We aimed to identify early clinical risk stratifiers at index hospitalization for major adverse cardiovascular events (MACE). Methods: We analysed 725 paediatric patients with possible/definite myocarditis enrolled in the prospective multicentre MYKKE registry (2013–24). Major adverse cardiovascular events included mechanical circulatory support (MCS), heart transplantation, or death during the initial admission. Model-based recursive partitioning and bootstrap-based logistic regression with multiple imputations were applied for risk stratifier selection out of 20 baseline variables. The model was externally validated in the Swedish SWEDCON cohort (n = 243). Discrimination was assessed by the area under the curve (AUC). Results: Among 725 patients [median age 14.3 years (IQR 4.0–16.4); 33% female], 88 (12.2%) experienced MACE (MCS 10.9%, transplantation 4.3%, death 2.2%). Model-based recursive partitioning identified left ventricular ejection fraction (LVEF) ≤39% as the only stable risk stratifier, delineating a ‘heart failure type’ in younger children (1.9 years; LVEF 24%), and a ‘chest pain type’ in adolescents with preserved LVEF (15.6 years; LVEF 59%). Left ventricular ejection fraction was confirmed as the sole robust risk stratifier (OR per 1% increase: .90; 95% CI .881–.917; P < .01; AUC .90, 95% CI .896–.903). In SWEDCON (7.4% MACE), discrimination was maintained (AUC .894, 95% CI .80–.991). Conclusion: Reduced LVEF at presentation was the only reproducible and externally validated risk stratifier of MACE during index hospitalization. Two age-associated clinical patterns were observed: a high-risk ‘heart failure type’ in younger children and low-risk ‘chest pain type’ in adolescents.
- 5 October 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (10)
REPLY
- Open Access
- 16 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 830, 154294
Mutational mapping of sequence variants within the arginine- and serine-rich domain of RNA binding motif protein 20
- 16 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 830, 154294
Open AccessMutational mapping of sequence variants within the arginine- and serine-rich domain of RNA binding motif protein 20
- 3 July 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
A high proportion of children with severe cardiomyopathies show both myocarditis and genetic predispositions
Aims: Severe cardiomyopathies in children may often demand a treatment with inclusion of mechanical circulatory support (MCS) or heart transplantation (HTx). Although these cardiomyopathies are not always hereditary, myocarditis may be regarded as a likely cause, if clinical course is not chronic. The aims of the study were to determine the genetic profile and prevalence of myocarditis in a pediatric population with clinical signs of severe cardiomyopathy. Methods and Results: We retrospectively included 106 pediatric and adolescent cardiomyopathy (CMPY) patients requiring HTx, MCS, or any in-hospital treatment. DNA-sequencing was done and sequence variants were classified based on ACMG guidelines. Myocarditis was diagnosed according to the clinical protocol. We overall genotyped 106 index patients; 92 (87%) patients receiving HTx or MCS, 14 (13%) received in hospital treatment. 87 patients (82%) had dilated cardiomyopathy and 54 (51%) carried a (likely) pathogenic (P/LP) variant with TNNI3 as one of the leading affected genes. In 84 genotyped patients (80%) myocarditis was examined. 57 (68%) of the 84 had myocarditis, with chronic lymphocytic myocarditis in 34 (40%) cases. In 28 (49%) of 57 patients with and 14 (52%) of 27 patients without myocarditis P/LP-variants were found. In 41 cases (39%) genotyping of the parents suggests de novo P/LP-variants (34%). Conclusions: In severe CMPY, genetic causes and myocarditis because of infection are common. About 50% of childhood cardiomyopathies are linked to pathogenic genetic variants. Myocarditis signatures commonly observed in severe pediatric cardiomyopathies, are not necessarily specific and the only reason for early presentation of heart failure. Genotyping in severe CMPY is essential to identify the causes of myocarditis. Providing genetic counseling may support families facing challenging psychosocial situations.
- 3 July 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
A high proportion of children with severe cardiomyopathies show both myocarditis and genetic predispositions
Aims: Severe cardiomyopathies in children may often demand a treatment with inclusion of mechanical circulatory support (MCS) or heart transplantation (HTx). Although these cardiomyopathies are not always hereditary, myocarditis may be regarded as a likely cause, if clinical course is not chronic. The aims of the study were to determine the genetic profile and prevalence of myocarditis in a pediatric population with clinical signs of severe cardiomyopathy. Methods and Results: We retrospectively included 106 pediatric and adolescent cardiomyopathy (CMPY) patients requiring HTx, MCS, or any in-hospital treatment. DNA-sequencing was done and sequence variants were classified based on ACMG guidelines. Myocarditis was diagnosed according to the clinical protocol. We overall genotyped 106 index patients; 92 (87%) patients receiving HTx or MCS, 14 (13%) received in hospital treatment. 87 patients (82%) had dilated cardiomyopathy and 54 (51%) carried a (likely) pathogenic (P/LP) variant with TNNI3 as one of the leading affected genes. In 84 genotyped patients (80%) myocarditis was examined. 57 (68%) of the 84 had myocarditis, with chronic lymphocytic myocarditis in 34 (40%) cases. In 28 (49%) of 57 patients with and 14 (52%) of 27 patients without myocarditis P/LP-variants were found. In 41 cases (39%) genotyping of the parents suggests de novo P/LP-variants (34%). Conclusions: In severe CMPY, genetic causes and myocarditis because of infection are common. About 50% of childhood cardiomyopathies are linked to pathogenic genetic variants. Myocarditis signatures commonly observed in severe pediatric cardiomyopathies, are not necessarily specific and the only reason for early presentation of heart failure. Genotyping in severe CMPY is essential to identify the causes of myocarditis. Providing genetic counseling may support families facing challenging psychosocial situations.
- Open Access
- 20 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108985
Erosion of the Right Atrial Wall After Implantation of a Patch-Like Septal Occluder
- 20 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108985
Open AccessErosion of the Right Atrial Wall After Implantation of a Patch-Like Septal Occluder
- Open Access
- 28 May 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 284, 109469
Stratification of children with myocarditis using radiomics signatures in LGE cardiovascular MRI
- 28 May 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 284, 109469
Open AccessStratification of children with myocarditis using radiomics signatures in LGE cardiovascular MRI
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e043468
Off‐Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience
Background: Transcatheter patent ductus arteriosus (PDA) closure can be challenging in cases of large PDA, complex anatomy, and small patient size. We aimed to assess the feasibility, efficacy and safety of the off‐label use of the multifunctional occluder in transcatheter PDA closure. Methods: A retrospective analysis was conducted on patients who underwent transcatheter PDA closure with the multifunctional occluder in 14 pediatric cardiology centers (5 countries) from 2018 to 2025. Results: A total of 77 procedures were performed on 75 patients, including 5 adults (6.7%). Among the 70 children (93.3%; median age: 0.8 years [range, 0.1–10 years], median procedural weight: 6.9 kg [range, 2.1–32.0 kg]), 35 (50.0%) weighed ≤6 kg (median procedural weight: 4.0 kg [range, 2.1–5.9 kg]). The PDA was large, with a minimal ductal diameter of 3.8 mm (range, 1.5–7.0 mm), short in 54.5%, and unrestrictive with increased pulmonary artery pressures in 51.6% of patients. The morphology was predominantly conical (Krichenko type A: 51.9%), with window‐type or complex morphologies representing 26.7% (Type B: 18.2%, Type D: 7.8%). Both arterial and venous femoral accesses were obtained in 87.0% cases, with deployment being antegrade in 77.9% and retrograde in 22.1%. Successful device deployment and release were achieved in 74 cases (96.1%). The rate of major adverse events was 5.2% including 1 early (1.3%) and 3 late complications (3.9%). No other adverse events were reported. Conclusions: The off‐label use of the multifunctional occluder device is a promising option for transcatheter PDA closure, demonstrating safety and efficacy in this series.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e043468
Open AccessOff‐Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience
Background: Transcatheter patent ductus arteriosus (PDA) closure can be challenging in cases of large PDA, complex anatomy, and small patient size. We aimed to assess the feasibility, efficacy and safety of the off‐label use of the multifunctional occluder in transcatheter PDA closure. Methods: A retrospective analysis was conducted on patients who underwent transcatheter PDA closure with the multifunctional occluder in 14 pediatric cardiology centers (5 countries) from 2018 to 2025. Results: A total of 77 procedures were performed on 75 patients, including 5 adults (6.7%). Among the 70 children (93.3%; median age: 0.8 years [range, 0.1–10 years], median procedural weight: 6.9 kg [range, 2.1–32.0 kg]), 35 (50.0%) weighed ≤6 kg (median procedural weight: 4.0 kg [range, 2.1–5.9 kg]). The PDA was large, with a minimal ductal diameter of 3.8 mm (range, 1.5–7.0 mm), short in 54.5%, and unrestrictive with increased pulmonary artery pressures in 51.6% of patients. The morphology was predominantly conical (Krichenko type A: 51.9%), with window‐type or complex morphologies representing 26.7% (Type B: 18.2%, Type D: 7.8%). Both arterial and venous femoral accesses were obtained in 87.0% cases, with deployment being antegrade in 77.9% and retrograde in 22.1%. Successful device deployment and release were achieved in 74 cases (96.1%). The rate of major adverse events was 5.2% including 1 early (1.3%) and 3 late complications (3.9%). No other adverse events were reported. Conclusions: The off‐label use of the multifunctional occluder device is a promising option for transcatheter PDA closure, demonstrating safety and efficacy in this series.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Three‐Year Clinical Follow‐Up in Children After Closure of Atrial Septal Defect With the reSept ASD Occluder
Introduction: Transcatheter closure for secundum‐type atrial septal defect (ASD II) with a bioresorbable septal occluder (as the “reSept ASD Occluder” by atHeart Medical) is a promising new technology, especially for their usage in children. Material: The reSept ASD Occluder by atHeart Medical AG, Baar, Switzerland, is a self‐centering double disk, repositionable, and retractable device with a bioresorbable framework (polylactic‐co‐glycolic acid), which is almost completely resorbed by 18–24 months postimplantation. Results: This manuscript reports the clinical follow‐up of now more than 3 years for the four first‐in‐child ASD device closures using a reSept ASD Occluder. This device exhibited a flat configuration without any obstruction or erosion of adjacent cardiac structures in all cases during follow‐up. Importantly, there was no evidence or clinical indications of systemic or local inflammation attributable to the ingrowth, reabsorption, and endothelialization processes of the device within our study population. The assessment of interatrial septum thickness, serving as a marker for local tissue reaction and inflammation and endothelialization, through serial echocardiograms did show only a mild increase from the time of implantation to 12‐month follow‐up, but no relevant further increase of interatrial septal thickness thereafter until 3‐year follow‐up. Conclusions: The CBSO/“reSept ASD Occluder” device system emerges as a promising alternative for transcatheter atrial septal defect (ASD) closure in pediatric patients. Our initial experience with its first‐in‐child implantation not only demonstrated effective and safe usage but also showed excellent results throughout the initial 3‐year clinical follow‐up period.
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Open AccessThree‐Year Clinical Follow‐Up in Children After Closure of Atrial Septal Defect With the reSept ASD Occluder
Introduction: Transcatheter closure for secundum‐type atrial septal defect (ASD II) with a bioresorbable septal occluder (as the “reSept ASD Occluder” by atHeart Medical) is a promising new technology, especially for their usage in children. Material: The reSept ASD Occluder by atHeart Medical AG, Baar, Switzerland, is a self‐centering double disk, repositionable, and retractable device with a bioresorbable framework (polylactic‐co‐glycolic acid), which is almost completely resorbed by 18–24 months postimplantation. Results: This manuscript reports the clinical follow‐up of now more than 3 years for the four first‐in‐child ASD device closures using a reSept ASD Occluder. This device exhibited a flat configuration without any obstruction or erosion of adjacent cardiac structures in all cases during follow‐up. Importantly, there was no evidence or clinical indications of systemic or local inflammation attributable to the ingrowth, reabsorption, and endothelialization processes of the device within our study population. The assessment of interatrial septum thickness, serving as a marker for local tissue reaction and inflammation and endothelialization, through serial echocardiograms did show only a mild increase from the time of implantation to 12‐month follow‐up, but no relevant further increase of interatrial septal thickness thereafter until 3‐year follow‐up. Conclusions: The CBSO/“reSept ASD Occluder” device system emerges as a promising alternative for transcatheter atrial septal defect (ASD) closure in pediatric patients. Our initial experience with its first‐in‐child implantation not only demonstrated effective and safe usage but also showed excellent results throughout the initial 3‐year clinical follow‐up period.
- Open Access
- 16 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2369
Prognostic Value of Speckle Tracking Echocardiography-Derived Strain in Unmasking Risk for Arrhythmias in Children with Myocarditis
Background/Objectives: Risk assessment in pediatric myocarditis is challenging, particularly when left ventricular ejection fraction (LVEF) is preserved. This study aimed to evaluate LV myocardial deformation using speckle-tracking echocardiography (STE)-derived longitudinal +strain (LS) and assessed its diagnostic and prognostic value in children with myocarditis. Methods: Retrospective STE-derived layer-specific LV LS analysis was performed on echocardiograms from patients within the multicenter, prospective registry for pediatric myocarditis “MYKKE”. Age- and sex-adjusted logistic regression and ROC analysis identified predictors of cardiac arrhythmias (ventricular tachycardia, ventricular fibrillation, atrioventricular blockage III°) and major adverse cardiac events (MACE: need for mechanical circulatory support (MCS), cardiac transplantation, and/or cardiac death). Results: Echocardiograms from 175 patients (median age 15 years, IQR 7.9–16.5 years; 70% male) across 13 centers were included. Cardiac arrhythmias occurred in 36 patients (21%), and MACE in 28 patients (16%). Impaired LV LS strongly correlated with reduced LVEF (r > 0.8). Impaired layer-specific LV LS, reduced LVEF, LV dilatation, and increased BSA-indexed LV mass, were associated with the occurrence of MACE and cardiac arrhythmias. In patients with preserved LVEF, LV LS alone predicted cardiac arrhythmias (p < 0.001), with optimal cutoff values of −18.0% for endocardial LV LS (sensitivity 0.69, specificity 0.94) and –17.0% for midmyocardial LV LS (sensitivity 0.81, specificity 0.75). Conclusions: In pediatric myocarditis, STE-derived LV LS is not only a valuable tool for assessing systolic myocardial dysfunction and predicting MACE but also identifies patients at risk for cardiac arrhythmias, even in the context of preserved LVEF.
- 16 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2369
Open AccessPrognostic Value of Speckle Tracking Echocardiography-Derived Strain in Unmasking Risk for Arrhythmias in Children with Myocarditis
Background/Objectives: Risk assessment in pediatric myocarditis is challenging, particularly when left ventricular ejection fraction (LVEF) is preserved. This study aimed to evaluate LV myocardial deformation using speckle-tracking echocardiography (STE)-derived longitudinal +strain (LS) and assessed its diagnostic and prognostic value in children with myocarditis. Methods: Retrospective STE-derived layer-specific LV LS analysis was performed on echocardiograms from patients within the multicenter, prospective registry for pediatric myocarditis “MYKKE”. Age- and sex-adjusted logistic regression and ROC analysis identified predictors of cardiac arrhythmias (ventricular tachycardia, ventricular fibrillation, atrioventricular blockage III°) and major adverse cardiac events (MACE: need for mechanical circulatory support (MCS), cardiac transplantation, and/or cardiac death). Results: Echocardiograms from 175 patients (median age 15 years, IQR 7.9–16.5 years; 70% male) across 13 centers were included. Cardiac arrhythmias occurred in 36 patients (21%), and MACE in 28 patients (16%). Impaired LV LS strongly correlated with reduced LVEF (r > 0.8). Impaired layer-specific LV LS, reduced LVEF, LV dilatation, and increased BSA-indexed LV mass, were associated with the occurrence of MACE and cardiac arrhythmias. In patients with preserved LVEF, LV LS alone predicted cardiac arrhythmias (p < 0.001), with optimal cutoff values of −18.0% for endocardial LV LS (sensitivity 0.69, specificity 0.94) and –17.0% for midmyocardial LV LS (sensitivity 0.81, specificity 0.75). Conclusions: In pediatric myocarditis, STE-derived LV LS is not only a valuable tool for assessing systolic myocardial dysfunction and predicting MACE but also identifies patients at risk for cardiac arrhythmias, even in the context of preserved LVEF.
- Open Access
- 30 December 2022
- Published by Hindawi Limited in Journal of Interventional Cardiology
- Vol. 2022, 1-4
Transcatheter Closure of Atrial Septal Defect with Carag Bioresorbable Septal Occluder™: First-in-Child Experience with 12-MonthFollow-Up
Background. Nowadays, transcatheter device closure of an atrial septal defect (ASD) is a standard approach in children. Potential early and long-term side effects or complications related to the metal framework of the devices are a known issue. A bioresorbable device such as the Carag Bioresorbable Septal Occluder (CBSO) could resolve such complications. Material and Results. The Carag Bioresorbable Septal Occluder (CBSO; Carag AG, Baar, Switzerland) is a self-centering double disk, repositionable, and retractable device with a bioresorbable framework (polylactic-co-glycolic acid), which is almost completely resorbed by 1824months postimplantation. This manuscript reports the four first-in-child ASD device closures using a CBSO. The patients age was median (IQ1-IQ3), 4.5years (47.25). Weight was 21.3kg (17.632.7). We demonstrated procedural feasibility and safety. Effective defect closure with the device was 100. Echocardiographic measurements of the thickness of the interatrial septum did not show any relevant increase over a 12-monthfollow-up period. There were no residual defects found after the procedure or later during the resorption process. The patients showed no evidence of any local or systemic inflammatory reaction. Conclusions. The CBSO device system could offer a new treatment option for transcatheter ASD device closure in the pediatric and adult fields. In our first-in-child experience, it was effectively and safely implanted. During the first 12 months of follow-up, no complications occurred.
- 30 December 2022
- Published by Hindawi Limited in Journal of Interventional Cardiology
- Vol. 2022, 1-4
Open AccessTranscatheter Closure of Atrial Septal Defect with Carag Bioresorbable Septal Occluder™: First-in-Child Experience with 12-MonthFollow-Up
Background. Nowadays, transcatheter device closure of an atrial septal defect (ASD) is a standard approach in children. Potential early and long-term side effects or complications related to the metal framework of the devices are a known issue. A bioresorbable device such as the Carag Bioresorbable Septal Occluder (CBSO) could resolve such complications. Material and Results. The Carag Bioresorbable Septal Occluder (CBSO; Carag AG, Baar, Switzerland) is a self-centering double disk, repositionable, and retractable device with a bioresorbable framework (polylactic-co-glycolic acid), which is almost completely resorbed by 1824months postimplantation. This manuscript reports the four first-in-child ASD device closures using a CBSO. The patients age was median (IQ1-IQ3), 4.5years (47.25). Weight was 21.3kg (17.632.7). We demonstrated procedural feasibility and safety. Effective defect closure with the device was 100. Echocardiographic measurements of the thickness of the interatrial septum did not show any relevant increase over a 12-monthfollow-up period. There were no residual defects found after the procedure or later during the resorption process. The patients showed no evidence of any local or systemic inflammatory reaction. Conclusions. The CBSO device system could offer a new treatment option for transcatheter ASD device closure in the pediatric and adult fields. In our first-in-child experience, it was effectively and safely implanted. During the first 12 months of follow-up, no complications occurred.